Latest Ratios: P/E Ratio 1.0x · EV/EBITDA N/A · ROE N/A. (2011–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $8M | $9M | $14M | $16M | $14M | $43M | $82M | $5M | $9M | $14M | $10M |
| Enterprise Value | $4M | $6M | $-7550157 | $-5079363 | $-25166654 | $-12147954 | $63M | $-17259985 | $-8268624 | $9M | $-11400994 |
| P/E Ratio → | 1.00 | 1.38 | — | — | — | — | — | — | — | — | — |
| P/S Ratio | 2.69 | 3.39 | 61.01 | 69.65 | 60.13 | 189.92 | 354.10 | 2.50 | 7.09 | 17.15 | 1.81 |
| P/B Ratio | — | — | — | 1.48 | 0.48 | 0.93 | 13.25 | 0.47 | 1.62 | — | 1.96 |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 2.02 | -33.41 | -22.48 | -111.36 | -53.75 | 271.74 | -7.91 | -6.73 | 12.04 | -2.06 |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 100.0% | 100.0% | 94.7% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | — | — | — |
| Operating Margin | -640.7% | -640.7% | -21835.4% | -8981.4% | -8684.5% | -7299.1% | -10819.5% | -994.0% | -1895.9% | -3270.3% | -427.4% |
| Net Profit Margin | 328.7% | 328.7% | -24192.0% | -8384.1% | -8391.2% | -7151.8% | -10890.5% | -985.0% | -1675.3% | -3061.2% | -354.6% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | — | — | — | -97.2% | -51.0% | -61.8% | -283.5% | -253.6% | -381.9% | — | -246.3% |
| ROA | 51.5% | 51.5% | -229.5% | -61.1% | -40.0% | -42.8% | -115.2% | -103.4% | -179.7% | -170.8% | -84.3% |
| ROIC | — | — | — | — | — | — | — | — | — | — | — |
| ROCE | -277.1% | -277.1% | -367.0% | -90.6% | -48.6% | -55.6% | -197.2% | -174.5% | -1037.5% | -637.4% | -164.0% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | — | — | — | — | — | — | — | — | — | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | — | — | -1.95 | -1.37 | -1.19 | -3.08 | -1.96 | -3.15 | — | -4.18 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | — | — | — | — | — | — | — | — | — | — | — |
Net cash position: cash ($4M) exceeds total debt ($0)
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 0.72 | 0.72 | 2.16 | 2.46 | 4.89 | 9.06 | 1.97 | 2.83 | 2.11 | 0.49 | 2.27 |
| Quick Ratio | 0.72 | 0.72 | 2.16 | 2.46 | 4.89 | 9.06 | 1.92 | 2.83 | 2.11 | 0.49 | 2.27 |
| Cash Ratio | 0.34 | 0.34 | 1.85 | 2.26 | 4.82 | 9.01 | 1.90 | 2.74 | 2.01 | 0.40 | 2.11 |
| Asset Turnover | — | 0.26 | 0.01 | 0.01 | 0.01 | 0.00 | 0.01 | 0.09 | 0.07 | 0.16 | 0.24 |
| Inventory Turnover | — | — | — | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | 496.35 | 2850.55 | 29.07 | 46.84 | 45.22 | 58.46 | 16.39 | 10.40 | 27.36 | 2.04 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | 99.9% | 72.6% | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 32.0% | 25.4% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 32.0% | 25.4% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Shares Outstanding | — | $8M | $2M | $839554 | $836329 | $673287 | $464095 | $38358 | $10997 | $1600 | $787 |
Imminent liquidity and dilution
According to recent market data, TRAW trades at a P/S ratio of 2.71, a multiple that appears disconnected from the company's lack of commercial revenue and suggests investors are pricing in speculative clinical success rather than any tangible fundamental value or current earnings power.
The P/E ratio of 1.01 is entirely misleading, as it is driven by non-recurring accounting gains rather than operational performance. Investors should view this valuation as a reflection of the company's remaining intellectual property value rather than a traditional earnings-based multiple.
As reported in financial statements, TRAW's operating margins have remained deeply negative, reaching -640.68% in recent periods, which highlights the structural inability of the current business model to cover its intensive research and development expenditures without relying on external capital injections.
The 100% gross margin is a technical artifact of the company's pre-commercial status and should not be interpreted as a sign of pricing power or operational efficiency. True earning power remains non-existent, and the company's profitability profile is likely to remain strained until a commercial product is successfully launched.
Based on historical data, TRAW's ROE has consistently trended into deep negative territory, reaching -195.0% in 2025Q4, which indicates that the company is effectively destroying shareholder capital as it burns through cash to fund early-stage clinical trials without generating any offsetting returns.
The lack of positive ROIC or ROE is characteristic of a clinical-stage biotech firm, but the trend suggests an accelerating decay in capital efficiency. Investors should monitor whether the shift to respiratory assets can eventually reverse this trend, though current metrics suggest significant value destruction.
As indicated by the company's reported figures, the current ratio has deteriorated significantly from 9.06 in 2021Q4 to a precarious 0.43 in 2026Q2, signaling that liquid assets are no longer sufficient to cover near-term liabilities as the cash runway nears exhaustion.
This liquidity profile suggests that the company is highly vulnerable to a funding crisis, necessitating immediate capital raises that will likely be dilutive to existing shareholders. The lack of inventory or receivables to bolster the quick ratio further underscores the firm's reliance on cash reserves.
The P/E ratio is the most commonly misapplied metric for TRAW, as it erroneously suggests the company is profitable when, in reality, the figure is distorted by non-cash accounting gains that bear no relationship to the firm's underlying cash-generating capacity or operational health.
Analysts should instead focus on quarterly net cash burn and the remaining cash runway to assess the company's viability. Using P/E to evaluate a pre-commercial biotech firm creates a false sense of security and obscures the reality of a business that is fundamentally dependent on external financing.
Includes 30+ ratios · 15 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying TRAW stock.
Traws Pharma, Inc.'s current P/E ratio is 1.0x. The historical average is 1.4x.
Based on historical data, Traws Pharma, Inc. is trading at a P/E of 1.0x. Compare with industry peers and growth rates for a complete picture.
Traws Pharma, Inc. has 100.0% gross margin and -640.7% operating margin.